Abstract
474O - Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have